Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-20
    E.g., 2018-09-20

Archive Search

Pages

55 results
11:34 PM, Nov 02, 2017  |  BC Week In Review | Company News  |  Sales & Marketing

NICE not recommending Eisai's lenvatinib for additional thyroid indications

The U.K.'s NICE issued draft guidance recommending against the use of Lenvima lenvatinib to treat advanced differentiated thyroid cancer that has spread to other parts of the body and cannot be operated on. The agency said...
2:33 PM, Sep 29, 2017  |  BC Week In Review | Company News  |  Sales & Marketing

NICE backs Bayer's Eylea

NASDAQ:REGN). It is a human fusion protein that binds all forms of VEGF-A and placental growth factor
8:12 AM, Sep 01, 2017  |  BC Week In Review | Company News  |  Sales & Marketing

NICE issues draft guidance against Cometriq and Caprelsa

NICE issued draft guidance recommending against the use of two drugs to treat medullary thyroid cancer in adults with unresectable, locally advanced or metastatic disease. The committee said clinical trial evidence showed Cometriq cabozantinib from...
12:53 PM, Aug 04, 2017  |  BC Week In Review | Company News  |  Sales & Marketing

Puma launches breast cancer drug Nerlynx in U.S.

Puma Biotechnology Inc. (NASDAQ:PBYI) launched Nerlynx oral neratinib in the U.S. as extended adjuvant treatment for patients with early stage HER2-overexpressed/amplified breast cancer who have received prior adjuvant Herceptin trastuzumab-based therapy. The wholesale acquisition cost...
2:48 PM, Apr 20, 2017  |  BC Week In Review | Company News  |  Sales & Marketing

Lenvima sales and marketing update

In a final benefit assessment, Germany’s Federal Joint Committee (G-BA) concluded that Kisplyx lenvatinib plus Afinitor everolimus provides additional benefit in treating advanced renal cell carcinoma (RCC) compared to everolimus alone. G-BA based the assessment...
10:32 AM, Mar 03, 2017  |  BC Week In Review | Company News  |  Sales & Marketing

Ocaliva, Erbitux and Vectibix sales and marketing update

The U.K.'s NICE issued a final appraisal determination (FAD) recommending the use of Ocaliva obeticholic acid from Intercept to treat primary biliary cholangitis (PBC). Specifically, NICE recommended Ocaliva's use in combination with ursodeoxycholic acid (UDCA)...
6:20 PM, Feb 23, 2017  |  BC Week In Review | Company News  |  Sales & Marketing

Cometriq sales and marketing update

The U.K.’s NICE issued draft guidance recommending against the use of Cometriq cabozantinib from Ipsen to treat advanced renal cell carcinoma (RCC) in adults previously treated with VEGF-targeted therapy. The committee said that the additional...
12:38 PM, Jan 06, 2017  |  BC Week In Review | Company News  |  Sales & Marketing

Kadcyla sales and marketing update

The U.K.'s NICE issued draft guidance recommending against the use of Kadcyla trastuzumab emtansine from Roche’s Genentech unit to treat HER2-positive, locally advanced or metastatic breast cancer due to its high cost. The agency said...
9:21 AM, Dec 16, 2016  |  BC Week In Review | Company News  |  Sales & Marketing

Neratinib sales and marketing update

Puma launched a managed access program outside the U.S. for neratinib to treat early stage HER2-positive breast cancer, HER2-positive metastatic breast cancer and HER2-mutated solid tumors. The oral inhibitor of HER1, HER2 and HER4 kinases...
9:14 AM, Dec 02, 2016  |  BC Week In Review | Company News  |  Sales & Marketing

Perjeta sales and marketing update

The U.K.’s NICE issued a final appraisal determination (FAD) recommending the use of Perjeta pertuzumab from Roche in combination with the pharma’s Herceptin trastuzumab and docetaxel for neoadjuvant treatment of HER2-positive, locally advanced, inflammatory or...

Pages